These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 1299692)

  • 1. Pharmaceutical regulation in the European Community: barriers to single market integration.
    Orzack LH; Kaitin KI; Lasagna L
    J Health Polit Policy Law; 1992; 17(4):847-68. PubMed ID: 1299692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Drugs in the European Union: the health-market complex].
    Antoñanzas F; Rodríguez R; Sacristán JA; Illa R
    Gac Sanit; 2005; 19(2):151-67. PubMed ID: 15860163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harmonising and competing for medicines regulation: how healthy are the European Union's systems of drug approval?
    Abraham J; Lewis G
    Soc Sci Med; 1999 Jun; 48(11):1655-67. PubMed ID: 10400264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restrictions on import of drugs for personal use within the European single market.
    Mäkinen MM; Rautava PT; Forsström JJ
    Eur J Public Health; 2002 Dec; 12(4):244-8. PubMed ID: 12506498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Policy making on data exclusivity in the European Union: from industrial interests to legal realities.
    Adamini S; Maarse H; Versluis E; Light DW
    J Health Polit Policy Law; 2009 Dec; 34(6):979-1010. PubMed ID: 20018988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Legal aspects of counteracting the trafficking of falsified medicines in the european union.
    Pashkov V; Soloviov A; Olefir A
    Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reorienting the course of medicines policy: actions are bearing fruit.
    Prescrire Int; 2003 Oct; 12(67):192-4. PubMed ID: 14619908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emergent patterns in the regulation of pharmaceuticals: institutions and interests in the United States, Canada, Britain, and France.
    Wiktorowicz ME
    J Health Polit Policy Law; 2003 Aug; 28(4):615-58. PubMed ID: 12956518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [EU law on marketing authorization of medicines. History, current state of development and perspectives].
    Nettesheim M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):705-12. PubMed ID: 18560781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical regulation in the single European market.
    Matthews D; Wilson C
    Med Law; 1998; 17(3):401-27. PubMed ID: 9922630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of the European regulatory approval system.
    Pignatti F; Boone H; Moulon I
    J Ambul Care Manage; 2004; 27(2):89-97. PubMed ID: 15069985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
    Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
    Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the pharmaceutical market in Poland after accession to the European Union.
    Willert PL
    Eur J Health Econ; 2007 Dec; 8(4):347-57. PubMed ID: 17186200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct-to-consumer advertising of prescription drugs: European Commission persists in putting industry's interests first.
    Prescrire Int; 2013 Jan; 22(134):24-5, 27. PubMed ID: 23373084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The network of official medicines control laboratories].
    Buchheit KH; Wanko R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1139-44. PubMed ID: 25192832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Problems in the regulatory policy of the drug market.
    Miziara NM; Coutinho DR
    Rev Saude Publica; 2015; 49():35. PubMed ID: 26083945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.